redhill biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. redhill has an experienced management team, board of directors and advisory board based in israel, the us, canada and europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise
Company profile
Ticker
RDHL
Exchange
Website
CEO
Dror Ben-Asher
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
RDHL stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
8 Apr 24
20-F
2023 FY
Annual report (foreign)
8 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Current report (foreign)
3 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
21 Mar 24
6-K
Current report (foreign)
20 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
11 Mar 24
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
2 Feb 24
SC 13G
CVI Investments, Inc.
1 Feb 24
SC 13G/A
Empery Asset Management, LP
8 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G
Empery Asset Management, LP
13 Jan 23
SC 13G
SABBY MANAGEMENT, LLC
4 Jan 23
SC 13G
Cosmo Pharmaceuticals N.V.
7 Mar 22
SC 13G/A
Ibex Investors LLC
27 Jan 22
SC 13G/A
Ibex Investors LLC
15 Jan 21
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 3 |
Closed positions | 5 |
Increased positions | 5 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 769.68 mm |
Total shares | 7.44 mm |
Total puts | 0.00 |
Total calls | 16.68 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Empery Asset Management | 5.91 mm | $0.00 |
Armistice Capital | 722.89 k | $368.68 mm |
Sabby Management | 635.01 k | $323.85 mm |
Citadel Advisors | 55.78 k | $28.45 mm |
Gagnon Securities | 47.97 k | $24.46 mm |
Two Sigma Securities | 25.38 k | $12.95 mm |
VIRT Virtu Financial | 19.87 k | $10.00 k |
We Are One Seven | 15.75 k | $8.03 mm |
Rhumbline Advisers | 3.01 k | $1.54 mm |
RY Royal Bank Of Canada | 2.25 k | $1.00 mm |
News
RedHill Biopharma Will Be Issued U.S. Patent Number 11,918,560 Tomorrow Titled "Serine Protease Inhibitor For Treating Coronavirus Infection"
4 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
1 Feb 24
Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings
25 Jan 24
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
25 Jan 24
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
25 Jan 24
Press releases
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
8 Apr 24
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
2 Apr 24
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
11 Mar 24
Nasdaq Stocks Under $1 to Watch Now! VTAK, IVP, ONCO, AKTS, RDHL
31 Jan 24
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
26 Jan 24